Railway Pension Investments Ltd decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 20.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,000 shares of the biopharmaceutical company’s stock after selling 28,700 shares during the quarter. Railway Pension Investments Ltd owned approximately 0.10% of Regeneron Pharmaceuticals worth $78,321,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Markel Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock valued at $56,083,000 after buying an additional 1,000 shares during the last quarter. Cibc World Market Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock valued at $4,481,000 after acquiring an additional 86 shares during the last quarter. Blair William & Co. IL lifted its holdings in shares of Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 23.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 93 shares during the period. Finally, Baird Financial Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 100.9% in the 1st quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after purchasing an additional 18,345 shares during the period. Institutional investors own 84.15% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on REGN. Oppenheimer upped their target price on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company a “market perform” rating in a research report on Monday, August 21st. Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $847.00 to $837.00 and set a “sector perform” rating for the company in a research report on Friday, November 3rd. Westpark Capital initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, September 15th. They set a “hold” rating on the stock. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $850.00 and gave the stock a “neutral” rating in a report on Monday, October 16th. Finally, Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the company from $720.00 to $992.00 in a report on Monday, August 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $903.64.
In related news, EVP Plew Daniel P. Van sold 6,197 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $841.71, for a total transaction of $5,216,076.87. Following the sale, the executive vice president now owns 21,508 shares of the company’s stock, valued at approximately $18,103,498.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Plew Daniel P. Van sold 6,197 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $841.71, for a total transaction of $5,216,076.87. Following the completion of the transaction, the executive vice president now directly owns 21,508 shares in the company, valued at $18,103,498.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total value of $82,790.00. Following the completion of the sale, the director now directly owns 18,547 shares in the company, valued at approximately $15,355,061.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,838 shares of company stock worth $18,294,246. 8.83% of the stock is owned by company insiders.
Regeneron Pharmaceuticals Stock Performance
REGN stock traded down $4.71 during midday trading on Tuesday, reaching $796.93. 34,115 shares of the company’s stock traded hands, compared to its average volume of 563,039. The firm has a market capitalization of $86.83 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 3.00 and a beta of 0.13. The company has a 50-day moving average price of $816.88 and a two-hundred day moving average price of $781.84. Regeneron Pharmaceuticals, Inc. has a 52 week low of $668.00 and a 52 week high of $853.97. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.47 and a current ratio of 5.18.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $11.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.58 by $2.01. The company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a return on equity of 18.61% and a net margin of 30.47%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $9.98 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.55 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
- Five stocks we like better than Regeneron Pharmaceuticals
- Learn Technical Analysis Skills to Master the Stock Market
- Zoom Video Communications: A tech phoenix ready to rise
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The only two airline stocks worth buying: One is a Goldman pick
- How to Find Cloud Software Company Stocks to Trade and Invest
- Ride the momentum: Apparel stocks soaring at 52-week highs
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.